

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Recent advances and emerging therapies in... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/7-87/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/7-87" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Recent advances and emerging therapies in anaplastic thyroid carcinoma" />
    
            <meta name="og:title" content="F1000Research Article: Recent advances and emerging therapies in anaplastic thyroid carcinoma.">
            <meta name="og:description" content="Read the latest article version by Maria E. Cabanillas, Mark Zafereo, Michelle D. Williams, Renata Ferrarotto, Ramona Dadu, Neil Gross, G. Brandon Gunn, Heath Skinner, Gilbert Cote, Horiana B. Grosu, Priyanka Iyer, Naifa L. Busaidy, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="14236">
            <meta name="article-id" content="13124">
            <meta name="dc.title" content="Recent advances and emerging therapies in anaplastic thyroid carcinoma">
            <meta name="dc.description" content="Anaplastic thyroid cancer is a rare and aggressive thyroid cancer with an overall survival measured in months. Because of this poor prognosis and often advanced age at presentation, these patients have traditionally been treated palliatively and referred for hospice. However, recent progress using novel therapies has energized the field, and several promising clinical trials are now available for these patients. This review will highlight this progress and the potential treatments that could pave the way to improved outcomes and quality of life for patients with this disease.">
            <meta name="dc.subject" content="BRAF, dabrafenib, trametinib, vemurafenib, squamous, sarcomatoid, anaplastic thyroid cancer, dedifferentiated, undifferentiated, targeted therapy, chemotherapy, NTRK">
            <meta name="dc.creator" content="Cabanillas, Maria E.">
            <meta name="dc.creator" content="Zafereo, Mark">
            <meta name="dc.creator" content="Williams, Michelle D.">
            <meta name="dc.creator" content="Ferrarotto, Renata">
            <meta name="dc.creator" content="Dadu, Ramona">
            <meta name="dc.creator" content="Gross, Neil">
            <meta name="dc.creator" content="Gunn, G. Brandon">
            <meta name="dc.creator" content="Skinner, Heath">
            <meta name="dc.creator" content="Cote, Gilbert">
            <meta name="dc.creator" content="Grosu, Horiana B.">
            <meta name="dc.creator" content="Iyer, Priyanka">
            <meta name="dc.creator" content="Busaidy, Naifa L.">
            <meta name="dc.date" content="2018/01/18">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.13124.1">
            <meta name="dc.source" content="F1000Research 2018 7:87">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="BRAF">
            <meta name="prism.keyword" content="dabrafenib">
            <meta name="prism.keyword" content="trametinib">
            <meta name="prism.keyword" content="vemurafenib">
            <meta name="prism.keyword" content="squamous">
            <meta name="prism.keyword" content="sarcomatoid">
            <meta name="prism.keyword" content="anaplastic thyroid cancer">
            <meta name="prism.keyword" content="dedifferentiated">
            <meta name="prism.keyword" content="undifferentiated">
            <meta name="prism.keyword" content="targeted therapy">
            <meta name="prism.keyword" content="chemotherapy">
            <meta name="prism.keyword" content="NTRK">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2018/01/18">
            <meta name="prism.volume" content="7">
            <meta name="prism.number" content="87">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.13124.1">
            <meta name="prism.url" content="https://f1000research.com/articles/7-87">
            <meta name="citation_title" content="Recent advances and emerging therapies in anaplastic thyroid carcinoma">
            <meta name="citation_abstract" content="Anaplastic thyroid cancer is a rare and aggressive thyroid cancer with an overall survival measured in months. Because of this poor prognosis and often advanced age at presentation, these patients have traditionally been treated palliatively and referred for hospice. However, recent progress using novel therapies has energized the field, and several promising clinical trials are now available for these patients. This review will highlight this progress and the potential treatments that could pave the way to improved outcomes and quality of life for patients with this disease.">
            <meta name="citation_description" content="Anaplastic thyroid cancer is a rare and aggressive thyroid cancer with an overall survival measured in months. Because of this poor prognosis and often advanced age at presentation, these patients have traditionally been treated palliatively and referred for hospice. However, recent progress using novel therapies has energized the field, and several promising clinical trials are now available for these patients. This review will highlight this progress and the potential treatments that could pave the way to improved outcomes and quality of life for patients with this disease.">
            <meta name="citation_keywords" content="BRAF, dabrafenib, trametinib, vemurafenib, squamous, sarcomatoid, anaplastic thyroid cancer, dedifferentiated, undifferentiated, targeted therapy, chemotherapy, NTRK">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Maria E. Cabanillas">
            <meta name="citation_author_institution" content="Department of Endocrine Neoplasia &amp; Hormonal Disorders, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA">
            <meta name="citation_author" content="Mark Zafereo">
            <meta name="citation_author_institution" content="Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA">
            <meta name="citation_author" content="Michelle D. Williams">
            <meta name="citation_author_institution" content="Department of Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA">
            <meta name="citation_author" content="Renata Ferrarotto">
            <meta name="citation_author_institution" content="Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, 515 Holcombe Blvd, Houston, TX, 77030, USA">
            <meta name="citation_author" content="Ramona Dadu">
            <meta name="citation_author_institution" content="Department of Endocrine Neoplasia &amp; Hormonal Disorders, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA">
            <meta name="citation_author" content="Neil Gross">
            <meta name="citation_author_institution" content="Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA">
            <meta name="citation_author" content="G. Brandon Gunn">
            <meta name="citation_author_institution" content="Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA">
            <meta name="citation_author" content="Heath Skinner">
            <meta name="citation_author_institution" content="Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA">
            <meta name="citation_author" content="Gilbert Cote">
            <meta name="citation_author_institution" content="Department of Endocrine Neoplasia &amp; Hormonal Disorders, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA">
            <meta name="citation_author" content="Horiana B. Grosu">
            <meta name="citation_author_institution" content="Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA">
            <meta name="citation_author" content="Priyanka Iyer">
            <meta name="citation_author_institution" content="Department of Endocrine Neoplasia &amp; Hormonal Disorders, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA">
            <meta name="citation_author" content="Naifa L. Busaidy">
            <meta name="citation_author_institution" content="Department of Endocrine Neoplasia &amp; Hormonal Disorders, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA">
            <meta name="citation_publication_date" content="2018/01/18">
            <meta name="citation_volume" content="7">
            <meta name="citation_publication_number" content="87">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.13124.1">
            <meta name="citation_firstpage" content="87">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/7-87/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/7-87.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=14236 /> <input type=hidden id=articleId name=articleId value=13124 /> <input type=hidden id=xmlUrl value="/articles/7-87/v1/xml"/> <input type=hidden id=xmlFileName value="-7-87-v1.xml"> <input type=hidden id=article_uuid value=45904f16-619d-400c-b8bd-c6693eee0d40 /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Recent advances and emerging therapies in anaplastic thyroid carcinoma"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.13124.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.13124.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/7-87"
  },
  "headline": "Recent advances and emerging therapies in anaplastic thyroid carcinoma",
  "datePublished": "2018-01-18T12:30:31",
  "dateModified": "2018-01-18T12:30:31",
  "author": [
    {
      "@type": "Person",
      "name": "Maria E. Cabanillas"
    },    {
      "@type": "Person",
      "name": "Mark Zafereo"
    },    {
      "@type": "Person",
      "name": "Michelle D. Williams"
    },    {
      "@type": "Person",
      "name": "Renata Ferrarotto"
    },    {
      "@type": "Person",
      "name": "Ramona Dadu"
    },    {
      "@type": "Person",
      "name": "Neil Gross"
    },    {
      "@type": "Person",
      "name": "G. Brandon Gunn"
    },    {
      "@type": "Person",
      "name": "Heath Skinner"
    },    {
      "@type": "Person",
      "name": "Gilbert Cote"
    },    {
      "@type": "Person",
      "name": "Horiana B. Grosu"
    },    {
      "@type": "Person",
      "name": "Priyanka Iyer"
    },    {
      "@type": "Person",
      "name": "Naifa L. Busaidy"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Anaplastic thyroid cancer is a rare and aggressive thyroid cancer with an overall survival measured in months. Because of this poor prognosis and often advanced age at presentation, these patients have traditionally been treated palliatively and referred for hospice. However, recent progress using novel therapies has energized the field, and several promising clinical trials are now available for these patients. This review will highlight this progress and the potential treatments that could pave the way to improved outcomes and quality of life for patients with this disease."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/7-87/v1",
            "name": "Recent advances and emerging therapies in anaplastic thyroid carcinoma"
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Recent advances and emerging therapies in anaplastic thyroid carcinoma </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=14236 data-id=13124 data-downloads="" data-views="" data-scholar="10.12688/f1000research.13124.1" data-recommended="" data-doi="10.12688/f1000research.13124.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/7-87/v1/pdf?article_uuid=45904f16-619d-400c-b8bd-c6693eee0d40" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-13124-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-13124-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-13124-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Cabanillas ME, Zafereo M, Williams MD <em>et al.</em> Recent advances and emerging therapies in anaplastic thyroid carcinoma [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):87 (<a class=new-orange href="https://doi.org/10.12688/f1000research.13124.1" target=_blank>https://doi.org/10.12688/f1000research.13124.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-13124-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=13124 id=track-article-signin-13124 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/13124?target=/articles/7-87/v1">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=14236 /> <input name=articleId type=hidden value=13124 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Recent advances and emerging therapies in anaplastic thyroid carcinoma</h1><span class=other-info> [version 1; peer review: 3 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class=""><a href="mailto:mcabani@mdanderson.org" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Maria E. Cabanillas</span></a><a href="https://orcid.org/0000-0002-5124-1811" target=_blank id=author-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-5124-1811</div><sup>1</sup>,&nbsp;</span><span class="">Mark Zafereo<sup>2</sup>,&nbsp;</span><span class="">Michelle D. Williams<sup>3</sup>,&nbsp;</span><a href="#" class=article-page-expand-authors>[...]&nbsp;</a><span class=article-page-hidden-authors>Renata Ferrarotto<sup>4</sup>,&nbsp;</span><span class=article-page-hidden-authors>Ramona Dadu<sup>1</sup>,&nbsp;</span><span class=article-page-hidden-authors>Neil Gross<sup>2</sup>,&nbsp;</span><span class=article-page-hidden-authors>G. Brandon Gunn<sup>5</sup>,&nbsp;</span><span class=article-page-hidden-authors>Heath Skinner<sup>5</sup>,&nbsp;</span><span class=article-page-hidden-authors>Gilbert Cote<sup>1</sup>,&nbsp;</span><span class="">Horiana B. Grosu<sup>6</sup>,&nbsp;</span><span class="">Priyanka Iyer<sup>1</sup>,&nbsp;</span><span class="">Naifa L. Busaidy<sup>1</sup></span><span class="author-display-control article-page-expand-authors f1r-icon icon-20_plus_big"></span><span class="author-display-control article-page-hidden-authors f1r-icon icon-12_minus_big"></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class=""><a href="mailto:mcabani@mdanderson.org" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Maria E. Cabanillas</span></a><a href="http://orcid.org/0000-0002-5124-1811" target=_blank id=mauthor-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-5124-1811</div><sup>1</sup>,&nbsp;</span><span class="">Mark Zafereo<sup>2</sup>,&nbsp;</span><a href="#" class=article-page-expand-authors>[...]&nbsp;</a><span class=article-page-hidden-authors>Michelle D. Williams<sup>3</sup>,&nbsp;</span><span class=article-page-hidden-authors>Renata Ferrarotto<sup>4</sup>,&nbsp;</span><span class=article-page-hidden-authors>Ramona Dadu<sup>1</sup>,&nbsp;</span><span class=article-page-hidden-authors>Neil Gross<sup>2</sup>,&nbsp;</span><span class=article-page-hidden-authors>G. Brandon Gunn<sup>5</sup>,&nbsp;</span><span class=article-page-hidden-authors>Heath Skinner<sup>5</sup>,&nbsp;</span><span class=article-page-hidden-authors>Gilbert Cote<sup>1</sup>,&nbsp;</span><span class=article-page-hidden-authors>Horiana B. Grosu<sup>6</sup>,&nbsp;</span><span class="">Priyanka Iyer<sup>1</sup>,&nbsp;</span><span class="">Naifa L. Busaidy<sup>1</sup></span><span class="author-display-control article-page-expand-authors f1r-icon icon-20_plus_big"></span><span class="author-display-control article-page-hidden-authors f1r-icon icon-12_minus_big"></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 18 Jan 2018 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.13124.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Department of Endocrine Neoplasia &amp; Hormonal Disorders, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA<br/> <sup>2</sup> Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA<br/> <sup>3</sup> Department of Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA<br/> <sup>4</sup> Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, 515 Holcombe Blvd, Houston, TX, 77030, USA<br/> <sup>5</sup> Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA<br/> <sup>6</sup> Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA<br/> <p> <div class=margin-bottom> Maria E. Cabanillas <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation </div> <div class=margin-bottom> Mark Zafereo <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> Michelle D. Williams <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> Renata Ferrarotto <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> Ramona Dadu <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> Neil Gross <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> G. Brandon Gunn <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> Heath Skinner <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> Gilbert Cote <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> Horiana B. Grosu <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> Priyanka Iyer <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> Naifa L. Busaidy <br/> <span>Roles: </span> Writing – Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=29715-29715></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=29716-29716></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=29714-29714></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Anaplastic thyroid cancer is a rare and aggressive thyroid cancer with an overall survival measured in months. Because of this poor prognosis and often advanced age at presentation, these patients have traditionally been treated palliatively and referred for hospice. However, recent progress using novel therapies has energized the field, and several promising clinical trials are now available for these patients. This review will highlight this progress and the potential treatments that could pave the way to improved outcomes and quality of life for patients with this disease. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> BRAF, dabrafenib, trametinib, vemurafenib, squamous, sarcomatoid, anaplastic thyroid cancer, dedifferentiated, undifferentiated, targeted therapy, chemotherapy, NTRK </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Maria E. Cabanillas (<a href="mailto:mcabani@mdanderson.org">mcabani@mdanderson.org</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Maria E. Cabanillas </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> MEC has received research funding from Roche Genentech, Kura, Eisai, and Exelixis. MEC has also received consultant fees from LOXO. NLB has received research funding from Bayer and Novartis and consulting fees from Eisai and Sanofi. BG, MDW, HS, PI, NG, RF, HG, and MZ have nothing to disclose. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The author(s) declared that no grants were involved in supporting this work. </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2018 Cabanillas ME <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Cabanillas ME, Zafereo M, Williams MD <em>et al.</em> Recent advances and emerging therapies in anaplastic thyroid carcinoma [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):87 (<a href="https://doi.org/10.12688/f1000research.13124.1" target=_blank>https://doi.org/10.12688/f1000research.13124.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 18 Jan 2018, <b>7</b>(F1000 Faculty Rev):87 (<a href="https://doi.org/10.12688/f1000research.13124.1" target=_blank>https://doi.org/10.12688/f1000research.13124.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 18 Jan 2018, <b>7</b>(F1000 Faculty Rev):87 (<a href="https://doi.org/10.12688/f1000research.13124.1" target=_blank>https://doi.org/10.12688/f1000research.13124.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d23673e338>Introduction</h2><p class="" id=d23673e341>Anaplastic thyroid carcinoma (ATC) is a rare form of thyroid cancer and one of the most aggressive cancers in humans. In part because of ATC’s rarity and short overall survival, very little progress has been made in the treatment of this disease until recently. An understanding of the molecular aberrations in this disease has advanced the field, leading to one of the most important treatment discoveries—BRAF targeting in <i>BRAF V600E</i>LN876569-mutant ATC. While this is an exciting discovery and represents substantial progress, only 25–45% of ATCs harbor a <i>BRAF</i> mutation<sup><a href="#ref-1">1</a>–<a href="#ref-3">3</a></sup>, and this treatment is not curative. However, a renewed interest in this disease will likely lead to a deeper comprehension of the mechanisms by which these tumors survive, that one day may result in better therapies and eventually a cure for this devastating disease.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d23673e360>Background</h2><p class="" id=d23673e363>The usual clinical presentation of ATC is of a patient with a rapidly expanding neck mass that may lead to compressive symptoms such as dysphagia and dyspnea. Patients may also have hoarseness due to vocal cord paralysis secondary to laryngeal nerve paralysis that can progress to stridor. However, some patients may have few symptoms until the disease is quite advanced and, therefore, most patients with ATC are not surgical candidates. Furthermore, approximately 46% of newly diagnosed patients present with widely metastatic disease at diagnosis<sup><a href="#ref-4">4</a></sup>. Patients may give a past history of long-standing goiter, thyroid nodules, or prior thyroid cancer. According to one series, in more than 80% of cases, there is a co-existing differentiated thyroid cancer (DTC) giving rise to a less differentiated or undifferentiated tumor<sup><a href="#ref-5">5</a></sup>.</p><p class="" id=d23673e374>The diagnosis of ATC can be made on fine needle aspiration, core biopsy, or surgical resection material. Fine needle aspiration is often the first attempt at biopsy, since this is the standard of care for thyroid nodules and suspected thyroid cancers. However, if the diagnosis of ATC is suspected, a core needle biopsy is preferable in order to perform genetic mutational analysis of the tumor. Many patients are not suspected to have ATC and are diagnosed only after undergoing thyroidectomy when the surgical pathology is reviewed.</p><p class="" id=d23673e377>The differential diagnosis of ATC includes lymphoma, poorly differentiated thyroid carcinoma (PDTC), poorly differentiated medullary thyroid carcinoma (MTC), squamous cell carcinoma from an adjacent site, and metastasis from other solid tumors. The diagnosis can be challenging because of the frequent loss of thyroid (TTF-1 and PAX8) and epithelial cell markers (cytokeratins). Morphologically, ATC is highly variable, from sarcomatoid, squamoid, and epithelioid to pleomorphic/giant cell cytologic features. ATC often grows as discohesive sheets of overtly malignant cells with high-grade features including marked necrosis and mitoses. An associated mixed inflammatory component is also present in the background.</p><p class="" id=d23673e380>According to the American Joint Committee on Cancer (AJCC) thyroid cancer staging system<sup><a href="#ref-6">6</a></sup>, all ATC patients are considered to have stage IV disease owing to the extremely high mortality rate. Stage IV disease is further broken down into stage IVA (intrathyroidal and surgically resectable without distant metastatic disease), stage IVB (extrathyroidal, with or without lymph node metastases but without distant metastatic disease), and stage IVC (distant metastatic disease at presentation).</p><p class="" id=d23673e388>Overall prognosis for ATC remains poor despite recent advances. The median overall survival remains around 3–5 months with a 1-year survival of approximately 20%<sup><a href="#ref-7">7</a></sup>. Patient factors associated with poorer prognosis include advanced age (&gt;60–70 years), male gender, presence of leukocytosis (&gt;10,000), and symptoms (such as rapidly growing tumor, pain in the neck, dyspnea, dysphagia, and hoarseness). Histologically, larger tumor size (&gt;5 cm), extrathyroidal invasion, giant cell and pleomorphic pattern, and/or presence of distant metastases are tumor factors that can portend a poor survival and predict treatment failure. Tumors with co-existing well-differentiated papillary thyroid carcinoma appear to fare better<sup><a href="#ref-2">2</a>,<a href="#ref-7">7</a>–<a href="#ref-9">9</a></sup>. In terms of treatment factors, patients with tumors that are surgically resectable and who are able to undergo external beam radiation have improved survival<sup><a href="#ref-4">4</a>,<a href="#ref-8">8</a>–<a href="#ref-16">16</a></sup>. The dose of external beam radiation is also prognostic, with patients who are able to undergo higher doses (&gt;60 Gy) surviving longer, even those who have not undergone complete resection<sup><a href="#ref-12">12</a>,<a href="#ref-17">17</a></sup>. Somatic tumor mutations may also affect outcomes. ATC tumors with <i>TERT</i> promotor mutations had a significantly shorter overall survival, particularly when these co-existed with either <i>BRAF</i> or <i>RAS</i> mutations<sup><a href="#ref-1">1</a></sup>. In another study, ATC patients with <i>TP53</i> mutations were shown to have a trend towards shorter time to failure after primary treatment<sup><a href="#ref-2">2</a></sup>.</p><p class="" id=d23673e443>Standard treatment for patients with stage IVA disease and some IVB patients is curative intent surgery, as this has been associated with longer survival<sup><a href="#ref-10">10</a>,<a href="#ref-14">14</a>,<a href="#ref-18">18</a>–<a href="#ref-20">20</a></sup>. Surgery should be performed by a surgeon with experience in advanced thyroid cancer. Post-operative radiation with radiosensitizing chemotherapy should be started within 4 weeks of surgery. Chemotherapy regimens are detailed in the American Thyroid Association guidelines for the management of patients with ATC<sup><a href="#ref-21">21</a></sup>. Unfortunately, surgery is not possible in the majority of patients, as most present with locally advanced and invasive disease. In general, if the patient has unresectable IVB disease, chemoradiation can be considered with the goal of local control. If the radiation field is too large or the chemoradiation treatment deemed too morbid for the patient, systemic therapy can be considered in these patients, particularly the novel targeted treatments discussed in the next section. Patients with IVC disease are the most challenging to manage, as balancing the need to control both local and distant metastatic disease can be difficult. Treatment guidelines recommend palliative radiation to control locoregional disease; however, our experience has been that palliative radiation provides little control. Thus, our practice is to treat these patients on clinical trials (preferable) or outside a trial with novel targeted therapies. A better understanding of the genetics of thyroid cancers has led to the use of novel therapies for ATC, which is the theme of this manuscript.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d23673e466>Genetics of anaplastic thyroid cancer</h2><p class="" id=d23673e469>The MAP kinase and PI3 kinase pathways are commonly activated in thyroid cancer. The common driver mutations that are seen in ATC are the same as those in DTC, as these tumors are usually derived from this class of tumor, particularly papillary, follicular, and Hurthle cell thyroid cancers. Thus, <i>BRAF</i>, <i>NRAS</i>, <i>KRAS</i>, and <i>HRAS</i> are common driver mutations seen in ATC. Mutations in tumor suppressor genes include <i>p53</i>, <i>NF1</i>, and <i>PTEN</i>. Secondary mutations such as <i>PIK3CA</i>, <i>TERT</i> promotor, <i>CTNNB1</i>, <i>EIF1AX</i>, <i>MTOR</i>, <i>CDKN2A</i>, and <i>AKT1</i> can co-exist with driver mutations and tumor suppressor gene mutations. <a href="#f1">Figure 1</a> shows the frequency of point mutations in ATC. The genetic rearrangements observed in papillary thyroid cancer, <i>RET</i>/<i>PTC</i> and <i>NTRK</i>, have also been described in ATC. Most recently, <i>ALK</i> and <i>ROS1</i> genetic rearrangements have also been described<sup><a href="#ref-22">22</a>,<a href="#ref-23">23</a></sup>.</p><a name=f1 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/14236/8fb25e2b-e511-4643-a84b-fe9b1b6180fd_figure1.gif"><img alt="8fb25e2b-e511-4643-a84b-fe9b1b6180fd_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/14236/8fb25e2b-e511-4643-a84b-fe9b1b6180fd_figure1.gif"></a><div class=caption><h3>Figure 1. Distribution of oncogenic mutations in anaplastic thyroid carcinoma.</h3><p id=d23673e552>Data compiled from three sources: COSMIC (<a target=xrefwindow href="http://cancer.sanger.ac.uk" id=d23673e554>cancer.sanger.ac.uk</a>)<sup><a href="#ref-3">3</a></sup>, Kunstman <i>et al.</i><sup><a href="#ref-24">24</a></sup>, and Landa <i>et al.</i><sup><a href="#ref-1">1</a></sup>. Genetic rearrangements are not represented on the graph.</p></div></div><p class="" id=d23673e578>Of all of the genetic mutations that occur in ATC, <i>BRAF V600E</i> is the most common (25–48%<sup><a href="#ref-1">1</a>–<a href="#ref-3">3</a>,<a href="#ref-24">24</a></sup>) actionable mutation, and therefore the most is known regarding novel therapies that target this mutation in ATC. However, other rare mutations and genetic aberrations may also prove to be actionable, such as <i>ALK</i> translocations. Unfortunately, at this time, the majority of mutations in ATC are not actionable, but targeting of the tumor microenvironment or common pathways is an alternative approach. <a href="#f2">Figure 2</a> shows drugs and drug targets of interest in thyroid cancer.</p><a name=f2 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/14236/8fb25e2b-e511-4643-a84b-fe9b1b6180fd_figure2.gif"><img alt="8fb25e2b-e511-4643-a84b-fe9b1b6180fd_figure2.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/14236/8fb25e2b-e511-4643-a84b-fe9b1b6180fd_figure2.gif"></a><div class=caption><h3>Figure 2. Schematic overview of the two most common pathways with genetic alterations in thyroid cancer—mitogen-activated protein kinase (MAPK) and phosphatidylinositide 3-kinase (PI3K) pathways.</h3><p id=d23673e610>The pathways can be activated by receptor tyrosine kinases (RTKs) being activated by growth factors or by overexpression of the receptor. Constitutive activation of the signaling pathways can be caused by mutations along the pathway, such as BRAF, RAS, PI3K, AKT, or mammalian target of rapamycin (mTOR), mutations in tumor suppressor genes, such as neurofibromin 1 (NF1) or phosphatase and tensin homolog (PTEN) mutations, or fusion RTKs, such as those in RET, neurotropic tropomyosin receptor kinase (NTRK), or anaplastic lymphoma kinase (ALK). Drugs that can inhibit at critical points in the pathway are listed in grey boxes. FGFR, fibroblast growth factor receptor; TSC1, tuberous sclerosis complex 1; TSC2, tuberous sclerosis complex 2; VEGFR, vascular endothelial growth factor receptor.</p></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d23673e620>Novel and promising therapies for ATC</h2><div class=section><a name=d23673e623 class=n-a></a><h3 class=section-title>Targeting genetic aberrations</h3><p class="" id=d23673e628><b><i>BRAF inhibitors</i>.</b> Several case reports of responses in <i>BRAF</i>-mutated ATC to selective BRAF inhibitors sparked interest in using these drugs in this disease<sup><a href="#ref-25">25</a>–<a href="#ref-27">27</a></sup>. Two basket trials that included <i>BRAF</i>-mutant ATC have been reported. The first trial reported had a very small cohort of ATC patients (n=7) treated with vemurafenib<sup><a href="#ref-28">28</a></sup>. In this study, one complete response (CR) and one partial response (PR) were reported. These two patients had relatively long responses and survival, as one was alive at the time of data cut-off after 12.7 months and the other lived for 15.5 months after starting the trial. Vemurafenib is FDA approved for use in the treatment of melanoma.</p><p class="" id=d23673e652>A basket trial with the selective BRAF inhibitor dabrafenib combined with the MEK inhibitor trametinib has, by far, reported the largest cohort of BRAF inhibitor-treated ATC patients<sup><a href="#ref-29">29</a></sup>. This trial was designed to enroll <i>BRAF</i>-mutated patients with nine different histologies, including an ATC cohort. Cohorts showing promising results were expanded. A total of 16 <i>BRAF</i>-mutated ATC patients, all previously treated with radiation or surgery, were reported; 11 of the 16 patients achieved PR. The median PFS and OS were not reached but were estimated to be 79% and 80% at 1 year, respectively. The most common adverse events were fatigue, pyrexia, and nausea. The combination of dabrafenib and trametinib is approved for <i>BRAF</i>-mutated melanoma and squamous cell carcinoma of the lung and has received Breakthrough Therapy Designation by the Food and Drug Administration for ATC.</p><p class="" id=d23673e668>The advantage of selective BRAF/MEK inhibitors is how rapidly these drugs can start to take effect. We previously published a case report of a <i>BRAF</i>-mutated ATC patient who failed several lines of therapy<sup><a href="#ref-26">26</a></sup>. The patient had stridor from significant airway obstruction prior to starting compassionate-use dabrafenib plus trametinib. This treatment prevented tracheostomy, and imaging performed 1 month after initiating treatment showed a dramatic response to therapy with a patent airway. Another way that the rapid onset of this combination therapy can be harnessed is by using these drugs as neoadjuvant therapy to shrink the tumor prior to surgery. Neoadjuvant vemurafenib has been studied in papillary thyroid cancer, and this strategy was deemed safe<sup><a href="#ref-30">30</a></sup>. In ATC, neoadjuvant BRAF plus MEK inhibitors could prove to be useful in patients with stage IVB disease, leading to regression and thereby allowing for complete surgical resection. Further studies are needed to determine if neoadjuvant treatment will result in improved locoregional control and/or survival.</p><p class="" id=d23673e682><b><i>NTRK inhibitors</i>.</b> There are two NTRK inhibitors at this time in clinical trials. Larotrectinib (LOXO) is a selective pan-TRK inhibitor that is highly potent against TRKA, B, and C. Trial results of three separate studies that included a total of 55 patients with <i>NTRK</i> fusions were reported at the American Society of Clinical Oncology (ASCO) Annual Meeting in 2017. There were 17 unique tumor types, including 9% thyroid cancer patients. The response rate in the 55-patient cohort was 78%, with four thyroid cancer patients achieving PR and one achieving CR. The histology of these five thyroid cancer patients was not reported. The drug was deemed tolerable, with fatigue, dizziness, anemia, and vomiting being the most common adverse events. Entrectinib (RXDX-101) is another pan-TRK inhibitor but also targets <i>ALK</i> and <i>ROS1</i> fusions. The drug is being studied in a basket trial for patients with <i>NTRK</i>, <i>ALK</i>, or <i>ROS</i> genetic rearrangements (NCT02568267). Results from the phase I trial have been reported; however, there were no thyroid cancer patients treated on this trial<sup><a href="#ref-31">31</a></sup>. Central nervous system activity was reported in one patient with <i>NTRK</i> fusion lung cancer who achieved CR in the brain.</p><p class="" id=d23673e716><b><i>Alk and ROS1 inhibitors</i>.</b> <i>ALK</i> mutations and fusions are uncommon events in thyroid cancer. They have been reported in 1.6% of papillary thyroid cancers, 4% of ATCs, and 9% of PDTCs in one series<sup><a href="#ref-22">22</a></sup>. Only one case of a thyroid cancer patient with <i>ALK</i> fusion treated with an ALK inhibitor has been reported in the literature. The patient was treated with crizotinib after failing standard therapy for ATC and achieved a remarkable response<sup><a href="#ref-32">32</a></sup>. A trial with ceritinib for <i>ALK</i> mutation or fusion is underway (NCT02289144). Only one case of <i>ROS1</i> rearrangement in papillary thyroid cancer has been reported. Although it has not been reported in ATC, it is possible that these exist in patients with ATC transformed from papillary thyroid cancer. Entrectinib (discussed above) is a pan-TRK, ALK, and ROS1 inhibitor that will be investigated in thyroid cancer patients in a currently enrolling basket trial (NCT02568267).</p><p class="" id=d23673e744><b><i>mTOR inhibitors</i>.</b> Targeting of <i>MTOR</i>, which is in the PI3 kinase pathway, has proven successful in other solid tumors such as renal cell carcinoma. Activating mutations along this pathway (<a href="#f1">Figure 1</a>), including <i>PIK3CA</i> and <i>MTOR</i>, as well as tumor suppressor loss of regulatory function mutations in <i>PTEN</i>, <i>TSC1</i>, and <i>TSC2</i>, are seen in ATC. <i>NF1</i> is another potential target of mTOR inhibitors, as <i>NF1</i>-mutated tumors can signal down the PI3 kinase pathway. Everolimus is the mTOR inhibitor most studied in thyroid cancer<sup><a href="#ref-33">33</a>–<a href="#ref-35">35</a></sup>. Several of these trials have included small numbers of ATC patients, but only occasional responses have been seen to date. One very impressive response was seen in a patient with a <i>TSC2</i> mutation. This patient responded to everolimus for 18 months before developing progression. Analysis of the tumor at progression revealed a new <i>MTOR</i> mutation<sup><a href="#ref-36">36</a></sup>. A study of a second-generation mTOR inhibitor with broad-spectrum inhibition of the mTOR complex is currently enrolling ATC patients (NCT02244463).</p></div><div class=section><a name=d23673e798 class=n-a></a><h3 class=section-title>Targeting the tumor microenvironment</h3><p class="" id=d23673e803><b><i>Antiangiogenics</i>.</b> Antiangiogenics are effective in DTCs and MTCs, and lenvatinib, sorafenib, vandetanib, and cabozantinib are FDA approved for these indications. These and other antiangiogenics<sup><a href="#ref-37">37</a>–<a href="#ref-40">40</a></sup> have also been studied in ATC, but only one antiangiogenic drug, lenvatinib, has shown sufficient efficacy to warrant further study as a single agent in a phase II trial. Lenvatinib was studied in a trial that included all three thyroid cancer types in Japan<sup><a href="#ref-41">41</a></sup>. This trial enrolled 17 ATC patients. Four patients (24%) achieved PR, 12 (71%) had stable disease, and one (6%) had progression as their best response. The median PFS in the ATC cohort was 7.4 months (95% CI: 1.7–12.9) and the median OS was 10.6 months (95% CI: 3.8–19.8). However, only 10 of the 17 tumors were centrally confirmed to be ATC. The favorable results of this study led to a larger, international, phase II trial to test the efficacy of lenvatinib in ATC (NCT02657369).</p><p class="" id=d23673e821>Another interesting trial that holds promise is a study with intensity modulated radiotherapy with radiosensitizing chemotherapy plus or minus pazopanib (randomly assigned; NCT01236547). This study—the first trial in ATC to complete anticipated enrollment—closed to new patient enrollment in 2016. The primary endpoint is OS; thus, the results are not expected until 2018.</p><p class="" id=d23673e824><b><i>Immunotherapy</i>.</b> At this time, there are no trial reports using immunotherapy in ATC. However, many immunotherapy trials for ATC are currently recruiting patients. Immunoprofiling of ATC tumors has shown that tumor-infiltrating lymphocytes are present in high numbers and that these tumors express programmed death-ligand 1 (PD-L1), which plays a role in suppressing the immune system<sup><a href="#ref-42">42</a>–<a href="#ref-46">46</a></sup>. Previous small studies have shown that tumor-associated macrophages (TAMs) are present in high frequencies in ATC compared with PDTC and DTC. Increased TAMs are associated with more invasive cancers and decreased survival, suggesting a tumorigenic role of TAMs in these cancers<sup><a href="#ref-47">47</a>–<a href="#ref-49">49</a></sup>. Although limited data exist with regard to functional characterization of TAMs, it is thought that TAMs closely resemble M2 (protumoral macrophages). In other cancer types, it has been shown that TAMs express programmed cell death-1 (PD-1), suggesting that PD-1/PD-L1 therapies may also function through a direct effect on macrophages<sup><a href="#ref-50">50</a></sup>. Additionally, TAM-focused therapeutic strategies could synergize with immunotherapy.</p><p class="" id=d23673e849>Several checkpoint inhibitors that target PD-1 or its ligand, PD-L1, are approved for other cancers. However, given our experience, because of the rate at which ATC tumors expand and the usually large size of ATC tumors, we believe that these drugs will require combination therapy with kinase inhibitors, cytotoxic chemotherapy, or radiation. In an immunocompetent mouse model of <i>BRAF</i>/<i>p53</i>-mutated ATC, the combination of a BRAF inhibitor plus anti-PD-L1 drugs led to far better responses than either drug alone<sup><a href="#ref-51">51</a></sup>, suggesting that combination therapy should be pursued in clinical trials. A clinical trial using this approach is currently underway (NCT03181100), as are other trials using combination checkpoint inhibitors (NCT03246958) and radiation plus immunotherapy (NCT03122496 and NCT03211117).</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d23673e866>Summary of the evolving management and future directions in ATC</h2><p class="" id=d23673e869>Owing to the staggeringly high failure rate in ATC and recent renewed interest in this disease, new paradigm shifts are rapidly evolving and being adopted by many leaders in the field. While routine molecular testing of ATC tumors is not currently in treatment guidelines and is controversial, our group feels strongly that all of these patients’ tumors should be tested upon diagnosis, at minimum, to determine BRAF status. Patients with <i>BRAF</i> mutations can be offered treatment with combination selective BRAF plus MEK inhibitor therapy. Some patients with initially unresectable disease may become resectable and could be considered for surgery if they respond to BRAF/MEK combination therapy. Patients who are well enough and want to consider clinical trials should have a broader panel of mutations and fusions interrogated in order to identify those who would be appropriate for selective inhibitor trials such as the selective NTRK or RET inhibitor trials. Other driver mutations that are identified may help identify a clinical trial that is appropriate for the patient, particularly as more targeted therapies become available. <a href="#f3">Figure 3</a> shows a proposed algorithm for selecting treatment in ATC patients and how the molecular information of the tumor can be used to help guide therapy, particularly in patients with a <i>BRAF V600E</i> mutation, since currently the most promising treatments are in these patients.</p><a name=f3 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/14236/8fb25e2b-e511-4643-a84b-fe9b1b6180fd_figure3.gif"><img alt="8fb25e2b-e511-4643-a84b-fe9b1b6180fd_figure3.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/14236/8fb25e2b-e511-4643-a84b-fe9b1b6180fd_figure3.gif"></a><div class=caption><h3>Figure 3. Proposed algorithm to determine best treatment in anaplastic thyroid carcinoma (ATC).</h3><p id=d23673e891>The most critical steps that lead to important decision points are in colored boxes and should be performed in tandem. Brown box: the airway should also be assessed by laryngoscopy. An unstable airway will require immediate management, which might include steroids, intubation, tracheostomy, or hospice if the patient has a poor performance status. Green boxes: full staging with cross-sectional, contrast-enhanced imaging of the brain, neck, chest, and abdomen as well as bone scan or PET/CT (preferable) should be performed in order to determine if there are distant metastases. If brain metastases are present, these may require radiation or surgery prior to any therapy. Based on the staging images and the patient’s performance status, the patient should be evaluated to determine if the tumor is resectable and a good surgical candidate. Blue box: a rapid test to determine <i>BRAF</i> status should be performed as soon as possible. Patients with a stable airway can be triaged to BRAF-directed therapy if a <i>BRAF V600E</i> mutation is present. If there is a treatment response that leads to resectability, surgery by an experienced surgeon may be considered for patients with low burden or no distant metastatic disease. In the absence of a <i>BRAF V600E</i> mutation, external beam radiation to the neck or systemic therapy on clinical trial is recommended. The decision between systemic therapy and external beam radiation in the <i>BRAF</i> wild-type subgroup will depend on local versus distant disease burden.</p></div></div><p class="" id=d23673e910>However, in order for patients to begin therapy before they deteriorate clinically, it is necessary to be able to rapidly test patients for pertinent mutations. The gold standard of molecular testing with next-generation sequencing can take over 1 month before results are known (far too long for patients with a rapidly lethal disease). Thus, the use of liquid biopsy, the testing of blood for circulating cell-free tumor DNA, which has been shown to be highly sensitive for identifying <i>BRAF</i> mutations in circulating DNA, should be employed routinely in patients who do not have available tissue specimens<sup><a href="#ref-52">52</a></sup>. In those with available tissue, immunohistochemistry for BRAF V600E on surgical specimens or core needle biopsy has proven to be a useful, rapid tool to identify BRAF-mutated ATC patients<sup><a href="#ref-53">53</a></sup>.</p><p class="" id=d23673e924>Resistance to kinase inhibitors remains a major obstacle in the treatment of ATC. Thus, moving away from single-agent therapy for ATC is one step in the right direction. Combinations of targeted therapy with immunotherapy may help overcome resistance and are currently being studied in clinical trials. Radiation plus systemic therapy with either immunotherapy or targeted therapies are also promising strategies for ATC patients. Also, due to the very high recurrence rate after definitive treatment with surgery and radiation, a systemic adjuvant approach should be studied in this setting.</p><p class="" id=d23673e928>The future is much more promising for ATC patients; however, many physicians continue to recommend hospice as the only option for these patients. Our hope in the current environment with potential promising targeted therapies is that more patients are aware of and will participate in clinical trials, particularly those whose tumors are molecularly driven. Increasing medical and public awareness of expanding clinical trial options for ATC, coupled with enhanced availability of tumor sequencing, may prime a cycle for rapid enrollment and outcome data in this rare disease.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d23673e1 class=n-a></a><h2 class=main-title id=d23874>Competing interests</h2><p class=metadata-entry><a name=d23673e273 class=n-a></a><p id=d23673e275> MEC has received research funding from Roche Genentech, Kura, Eisai, and Exelixis. MEC has also received consultant fees from LOXO. NLB has received research funding from Bayer and Novartis and consulting fees from Eisai and Sanofi. BG, MDW, HS, PI, NG, RF, HG, and MZ have nothing to disclose.</p></p></div><div class=back-section><a name=d23673e1 class=n-a></a><h2 class=main-title id=d23876>Grant information</h2><p>The author(s) declared that no grants were involved in supporting this work.</p></div><div class=back-section><a name=d23673e935 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d24043>References</h2><div class="section ref-list"><a name=d23673e935 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726148129"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23673e942 class=n-a></a>Landa I, Ibrahimpasic T, Boucai L, <i> et al.</i>: Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. <i>J Clin Invest.</i> 2016; <b>126</b>(3): 1052–66. <a target=xrefwindow id=d23673e953 href="http://www.ncbi.nlm.nih.gov/pubmed/26878173">PubMed Abstract </a> | <a target=xrefwindow id=d23673e956 href="https://doi.org/10.1172/JCI85271">Publisher Full Text </a> | <a target=xrefwindow id=d23673e960 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4767360">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726148129">F1000 Recommendation</a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d23673e973 class=n-a></a>Rao SN, Zafereo M, Dadu R, <i> et al.</i>: Patterns of Treatment Failure in Anaplastic Thyroid Carcinoma. <i>Thyroid.</i> 2017; <b>27</b>(5): 672–81. <a target=xrefwindow id=d23673e984 href="http://www.ncbi.nlm.nih.gov/pubmed/28068873">PubMed Abstract </a> | <a target=xrefwindow id=d23673e987 href="https://doi.org/10.1089/thy.2016.0395">Publisher Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d23673e996 class=n-a></a>Forbes SA, Beare D, Gunasekaran P, <i> et al.</i>: COSMIC: exploring the world's knowledge of somatic mutations in human cancer. <i>Nucleic Acids Res.</i> 2015; <b>43</b>(Database issue): D805–11. <a target=xrefwindow id=d23673e1007 href="http://www.ncbi.nlm.nih.gov/pubmed/25355519">PubMed Abstract </a> | <a target=xrefwindow id=d23673e1010 href="https://doi.org/10.1093/nar/gku1075">Publisher Full Text </a> | <a target=xrefwindow id=d23673e1014 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4383913">Free Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d23673e1023 class=n-a></a>McIver B, Hay ID, Giuffrida DF, <i> et al.</i>: Anaplastic thyroid carcinoma: a 50-year experience at a single institution. <i>Surgery.</i> 2001; <b>130</b>(6): 1028–34. <a target=xrefwindow id=d23673e1034 href="http://www.ncbi.nlm.nih.gov/pubmed/11742333">PubMed Abstract </a> | <a target=xrefwindow id=d23673e1037 href="https://doi.org/10.1067/msy.2001.118266">Publisher Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d23673e1046 class=n-a></a>Aldinger KA, Samaan NA, Ibanez M, <i> et al.</i>: Anaplastic carcinoma of the thyroid: <i>a review of 84 cases of spindle and giant cell carcinoma of the thyroid</i>. <i>Cancer.</i> 1978; <b>41</b>(6): 2267–75. <a target=xrefwindow id=d23673e1060 href="http://www.ncbi.nlm.nih.gov/pubmed/657091">PubMed Abstract </a> | <a target="xrefwindow" id="d23673e1064" href="https://doi.org/10.1002/1097-0142(197806)41:6<2267::AID-CNCR2820410627&gt;3.0.CO;2-7">Publisher Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d23673e1074 class=n-a></a>Greene FL, Page DL, Fleming ID, <i> et al.</i>: AJCC cancer staging manual. 6th edition. New York: Springer; 2002. <a target=xrefwindow id=d23673e1079 href="https://doi.org/10.1007/978-1-4757-3656-4">Publisher Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d23673e1088 class=n-a></a>Kebebew E, Greenspan FS, Clark OH, <i> et al.</i>: Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. <i>Cancer.</i> 2005; <b>103</b>(7): 1330–5. <a target=xrefwindow id=d23673e1099 href="http://www.ncbi.nlm.nih.gov/pubmed/15739211">PubMed Abstract </a> | <a target=xrefwindow id=d23673e1102 href="https://doi.org/10.1002/cncr.20936">Publisher Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d23673e1111 class=n-a></a>Kim TY, Kim KW, Jung TS, <i> et al.</i>: Prognostic factors for Korean patients with anaplastic thyroid carcinoma. <i>Head Neck.</i> 2007; <b>29</b>(8): 765–72. <a target=xrefwindow id=d23673e1122 href="http://www.ncbi.nlm.nih.gov/pubmed/17274052">PubMed Abstract </a> | <a target=xrefwindow id=d23673e1125 href="https://doi.org/10.1002/hed.20578">Publisher Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d23673e1134 class=n-a></a>Sugitani I, Miyauchi A, Sugino K, <i> et al.</i>: Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC Research Consortium of Japan cohort study of 677 patients. <i>World J Surg.</i> 2012; <b>36</b>(6): 1247–54. <a target=xrefwindow id=d23673e1145 href="http://www.ncbi.nlm.nih.gov/pubmed/22311136">PubMed Abstract </a> | <a target=xrefwindow id=d23673e1148 href="https://doi.org/10.1007/s00268-012-1437-z">Publisher Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d23673e1157 class=n-a></a>Haigh PI, Ituarte PH, Wu HS, <i> et al.</i>: Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. <i>Cancer.</i> 2001; <b>91</b>(12): 2335–42. <a target=xrefwindow id=d23673e1168 href="http://www.ncbi.nlm.nih.gov/pubmed/11413523">PubMed Abstract </a> | <a target="xrefwindow" id="d23673e1171" href="https://doi.org/10.1002/1097-0142(20010615)91:12<2335::AID-CNCR1266&gt;3.0.CO;2-1">Publisher Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/731988472"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23673e1180 class=n-a></a>Prasongsook N, Kumar A, Chintakuntlawar AV, <i> et al.</i>: Survival in Response to Multimodal Therapy in Anaplastic Thyroid Cancer. <i>J Clin Endocrinol Metab.</i> 2017; <b>102</b>(12): 4506–14. <a target=xrefwindow id=d23673e1191 href="http://www.ncbi.nlm.nih.gov/pubmed/29029287">PubMed Abstract </a> | <a target=xrefwindow id=d23673e1194 href="https://doi.org/10.1210/jc.2017-01180">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/731988472">F1000 Recommendation</a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726158252"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23673e1208 class=n-a></a>Glaser SM, Mandish SF, Gill BS, <i> et al.</i>: Anaplastic thyroid cancer: Prognostic factors, patterns of care, and overall survival. <i>Head Neck.</i> 2016; <b>38 Suppl 1</b>: E2083–90. <a target=xrefwindow id=d23673e1219 href="http://www.ncbi.nlm.nih.gov/pubmed/26894506">PubMed Abstract </a> | <a target=xrefwindow id=d23673e1222 href="https://doi.org/10.1002/hed.24384">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726158252">F1000 Recommendation</a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d23673e1235 class=n-a></a>Pierie JP, Muzikansky A, Gaz RD, <i> et al.</i>: The effect of surgery and radiotherapy on outcome of anaplastic thyroid carcinoma. <i>Ann Surg Oncol.</i> 2002; <b>9</b>(1): 57–64. <a target=xrefwindow id=d23673e1246 href="http://www.ncbi.nlm.nih.gov/pubmed/11833496">PubMed Abstract </a> | <a target=xrefwindow id=d23673e1249 href="https://doi.org/10.1245/aso.2002.9.1.57">Publisher Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d23673e1258 class=n-a></a>Kihara M, Miyauchi A, Yamauchi A, <i> et al.</i>: Prognostic factors of anaplastic thyroid carcinoma. <i>Surg Today.</i> 2004; <b>34</b>(5): 394–8. <a target=xrefwindow id=d23673e1269 href="http://www.ncbi.nlm.nih.gov/pubmed/15108075">PubMed Abstract </a> | <a target=xrefwindow id=d23673e1272 href="https://doi.org/10.1007/s00595-003-2737-6">Publisher Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d23673e1281 class=n-a></a>Are C, Shaha AR: Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. <i>Ann Surg Oncol.</i> 2006; <b>13</b>(4): 453–64. <a target=xrefwindow id=d23673e1289 href="http://www.ncbi.nlm.nih.gov/pubmed/16474910">PubMed Abstract </a> | <a target=xrefwindow id=d23673e1292 href="https://doi.org/10.1245/ASO.2006.05.042">Publisher Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d23673e1301 class=n-a></a>Akaishi J, Sugino K, Kitagawa W, <i> et al.</i>: Prognostic factors and treatment outcomes of 100 cases of anaplastic thyroid carcinoma. <i>Thyroid.</i> 2011; <b>21</b>(11): 1183–9. <a target=xrefwindow id=d23673e1312 href="http://www.ncbi.nlm.nih.gov/pubmed/21936674">PubMed Abstract </a> | <a target=xrefwindow id=d23673e1315 href="https://doi.org/10.1089/thy.2010.0332">Publisher Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d23673e1324 class=n-a></a>Pezzi TA, Mohamed AS, Sheu T, <i> et al.</i>: Radiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma: Outcomes from the National Cancer Data Base. <i>Cancer.</i> 2017; <b>123</b>(9): 1653–61. <a target=xrefwindow id=d23673e1335 href="http://www.ncbi.nlm.nih.gov/pubmed/28026871">PubMed Abstract </a> | <a target=xrefwindow id=d23673e1338 href="https://doi.org/10.1002/cncr.30493">Publisher Full Text </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d23673e1348 class=n-a></a>Swaak-Kragten AT, de Wilt JH, Schmitz PI, <i> et al.</i>: Multimodality treatment for anaplastic thyroid carcinoma--treatment outcome in 75 patients. <i>Radiother Oncol.</i> 2009; <b>92</b>(1): 100–4. <a target=xrefwindow id=d23673e1359 href="http://www.ncbi.nlm.nih.gov/pubmed/19328572">PubMed Abstract </a> | <a target=xrefwindow id=d23673e1362 href="https://doi.org/10.1016/j.radonc.2009.02.016">Publisher Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d23673e1371 class=n-a></a>de Crevoisier R, Baudin E, Bachelot A, <i> et al.</i>: Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy. <i>Int J Radiat Oncol Biol Phys.</i> 2004; <b>60</b>(4): 1137–43. <a target=xrefwindow id=d23673e1382 href="http://www.ncbi.nlm.nih.gov/pubmed/15519785">PubMed Abstract </a> | <a target=xrefwindow id=d23673e1385 href="https://doi.org/10.1016/j.ijrobp.2004.05.032">Publisher Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d23673e1394 class=n-a></a>Kumar A, Prasongsook N, Kasperbauer J, <i> et al.</i>: Outcomes in response to aggressive multi-modal therapy in anaplastic thyroid cancer: the mayo clinic experience. <i>Thyroid.</i> 2015; <b>25</b>(Supplement 1): abstr 72. </span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d23673e1412 class=n-a></a>Smallridge RC, Ain KB, Asa SL, <i> et al.</i>: American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. <i>Thyroid.</i> 2012; <b>22</b>(11): 1104–39. <a target=xrefwindow id=d23673e1423 href="http://www.ncbi.nlm.nih.gov/pubmed/23130564">PubMed Abstract </a> | <a target=xrefwindow id=d23673e1426 href="https://doi.org/10.1089/thy.2012.0302">Publisher Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d23673e1435 class=n-a></a>Kelly LM, Barila G, Liu P, <i> et al.</i>: Identification of the transforming <i>STRN-ALK</i> fusion as a potential therapeutic target in the aggressive forms of thyroid cancer. <i>Proc Natl Acad Sci U S A.</i> 2014; <b>111</b>(11): 4233–8. <a target=xrefwindow id=d23673e1449 href="http://www.ncbi.nlm.nih.gov/pubmed/24613930">PubMed Abstract </a> | <a target=xrefwindow id=d23673e1453 href="https://doi.org/10.1073/pnas.1321937111">Publisher Full Text </a> | <a target=xrefwindow id=d23673e1456 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3964116">Free Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d23673e1465 class=n-a></a>Ritterhouse LL, Wirth LJ, Randolph GW, <i> et al.</i>: <i>ROS1</i> Rearrangement in Thyroid Cancer. <i>Thyroid.</i> 2016; <b>26</b>(6): 794–7. <a target=xrefwindow id=d23673e1479 href="http://www.ncbi.nlm.nih.gov/pubmed/27089969">PubMed Abstract </a> | <a target=xrefwindow id=d23673e1483 href="https://doi.org/10.1089/thy.2016.0101">Publisher Full Text </a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725308809"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23673e1493 class=n-a></a>Kunstman JW, Juhlin CC, Goh G, <i> et al.</i>: Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing. <i>Hum Mol Genet.</i> 2015; <b>24</b>(8): 2318–29. <a target=xrefwindow id=d23673e1504 href="http://www.ncbi.nlm.nih.gov/pubmed/25576899">PubMed Abstract </a> | <a target=xrefwindow id=d23673e1507 href="https://doi.org/10.1093/hmg/ddu749">Publisher Full Text </a> | <a target=xrefwindow id=d23673e1511 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4380073">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725308809">F1000 Recommendation</a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d23673e1524 class=n-a></a>Rosove MH, Peddi PF, Glaspy JA: BRAF V600E inhibition in anaplastic thyroid cancer. <i>N Engl J Med.</i> 2013; <b>368</b>(7): 684–5. <a target=xrefwindow id=d23673e1532 href="http://www.ncbi.nlm.nih.gov/pubmed/23406047">PubMed Abstract </a> | <a target=xrefwindow id=d23673e1535 href="https://doi.org/10.1056/NEJMc1215697">Publisher Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d23673e1544 class=n-a></a>Cabanillas ME, Busaidy NL, Khan SA, <i> et al.</i>: Molecular diagnostics and anaplastic thyroid carcinoma: The time has come to harvest the high hanging fruit. <i>Int J Endocr Oncol.</i> 2016; <b>3</b>(3): 221–33. <a target=xrefwindow id=d23673e1555 href="https://doi.org/10.2217/ije-2016-0007">Publisher Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d23673e1564 class=n-a></a>Prager GW, Koperek O, Mayerhoefer ME, <i> et al.</i>: Sustained Response to Vemurafenib in a <i>BRAF<sup>V600E</sup></i>-Mutated Anaplastic Thyroid Carcinoma Patient. <i>Thyroid.</i> 2016; <b>26</b>(10): 1515–6. <a target=xrefwindow id=d23673e1580 href="http://www.ncbi.nlm.nih.gov/pubmed/27532222">PubMed Abstract </a> | <a target=xrefwindow id=d23673e1584 href="https://doi.org/10.1089/thy.2015.0575">Publisher Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725728960"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23673e1593 class=n-a></a>Hyman DM, Puzanov I, Subbiah V, <i> et al.</i>: Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations. <i>N Engl J Med.</i> 2015; <b>373</b>(8): 726–36. <a target=xrefwindow id=d23673e1607 href="http://www.ncbi.nlm.nih.gov/pubmed/26287849">PubMed Abstract </a> | <a target=xrefwindow id=d23673e1611 href="https://doi.org/10.1056/NEJMoa1502309">Publisher Full Text </a> | <a target=xrefwindow id=d23673e1614 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4971773">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725728960">F1000 Recommendation</a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d23673e1627 class=n-a></a>Subbiah V, Kreitman RJ, Wainberg ZA, <i> et al.</i>: Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic <i>BRAF</i> V600-Mutant Anaplastic Thyroid Cancer. <i>J Clin Oncol.</i> 2018; <b>36</b>(1): 7–13. <a target=xrefwindow id=d23673e1641 href="http://www.ncbi.nlm.nih.gov/pubmed/29072975">PubMed Abstract </a> | <a target=xrefwindow id=d23673e1645 href="https://doi.org/10.1200/JCO.2017.73.6785">Publisher Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d23673e1655 class=n-a></a>Cabanillas ME, Busaidy NL, Zafereo M, <i> et al.</i>: Neoadjuvant vemurafenib in patients with locally advanced papillary thyroid cancer (PTC). <i>European Thyroid Journal.</i> 2017; <b>6</b>(Suppl 1, abstr OP-06-39): 23–118. </span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727294853"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23673e1673 class=n-a></a>Drilon A, Siena S, Ou SI, <i> et al.</i>: Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). <i>Cancer Discov.</i> 2017; <b>7</b>(4): 400–9. <a target=xrefwindow id=d23673e1684 href="http://www.ncbi.nlm.nih.gov/pubmed/28183697">PubMed Abstract </a> | <a target=xrefwindow id=d23673e1687 href="https://doi.org/10.1158/2159-8290.CD-16-1237">Publisher Full Text </a> | <a target=xrefwindow id=d23673e1691 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5380583">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727294853">F1000 Recommendation</a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718414678"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23673e1704 class=n-a></a>Godbert Y, Henriques de Figueiredo B, Bonichon F, <i> et al.</i>: Remarkable Response to Crizotinib in Woman With Anaplastic Lymphoma Kinase-Rearranged Anaplastic Thyroid Carcinoma. <i>J Clin Oncol.</i> 2015; <b>33</b>(20): e84–7. <a target=xrefwindow id=d23673e1715 href="http://www.ncbi.nlm.nih.gov/pubmed/24687827">PubMed Abstract </a> | <a target=xrefwindow id=d23673e1718 href="https://doi.org/10.1200/JCO.2013.49.6596">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718414678">F1000 Recommendation</a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718113892"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23673e1731 class=n-a></a>Lim SM, Chang H, Yoon MJ, <i> et al.</i>: A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes. <i>Ann Oncol.</i> 2013; <b>24</b>(12): 3089–94. <a target=xrefwindow id=d23673e1742 href="http://www.ncbi.nlm.nih.gov/pubmed/24050953">PubMed Abstract </a> | <a target=xrefwindow id=d23673e1745 href="https://doi.org/10.1093/annonc/mdt379">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718113892">F1000 Recommendation</a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d23673e1758 class=n-a></a>Lorch JH, Busaidy N, Ruan DT, <i> et al.</i>: A phase II study of everolimus in patients with aggressive RAI refractory (RAIR) thyroid cancer (TC). <i>JCO.</i> 2013; <b>21</b>(suppl): abstr 6023. <a target=xrefwindow id=d23673e1769 href="http://ascopubs.org/doi/abs/10.1200/jco.2013.31.15_suppl.6023">Reference Source</a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d23673e1778 class=n-a></a>Schneider TC, de Wit D, Links TP, <i> et al.</i>: Everolimus in Patients With Advanced Follicular-Derived Thyroid Cancer: Results of a Phase II Clinical Trial. <i>J Clin Endocrinol Metab.</i> 2017; <b>102</b>(2): 698–707. <a target=xrefwindow id=d23673e1789 href="http://www.ncbi.nlm.nih.gov/pubmed/27870581">PubMed Abstract </a> | <a target=xrefwindow id=d23673e1792 href="https://doi.org/10.1210/jc.2016-2525">Publisher Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/720319917"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23673e1802 class=n-a></a>Wagle N, Grabiner BC, Van Allen EM, <i> et al.</i>: Response and acquired resistance to everolimus in anaplastic thyroid cancer. <i>N Engl J Med.</i> 2014; <b>371</b>(15): 1426–33. <a target=xrefwindow id=d23673e1813 href="http://www.ncbi.nlm.nih.gov/pubmed/25295501">PubMed Abstract </a> | <a target=xrefwindow id=d23673e1816 href="https://doi.org/10.1056/NEJMoa1403352">Publisher Full Text </a> | <a target=xrefwindow id=d23673e1820 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4564868">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/720319917">F1000 Recommendation</a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717953610"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23673e1833 class=n-a></a>Bible KC, Suman VJ, Menefee ME, <i> et al.</i>: A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer. <i>J Clin Endocrinol Metab.</i> 2012; <b>97</b>(9): 3179–84. <a target=xrefwindow id=d23673e1844 href="http://www.ncbi.nlm.nih.gov/pubmed/22774206">PubMed Abstract </a> | <a target=xrefwindow id=d23673e1847 href="https://doi.org/10.1210/jc.2012-1520">Publisher Full Text </a> | <a target=xrefwindow id=d23673e1851 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3431569">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717953610">F1000 Recommendation</a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717964469"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23673e1864 class=n-a></a>Savvides P, Nagaiah G, Lavertu P, <i> et al.</i>: Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid. <i>Thyroid.</i> 2013; <b>23</b>(5): 600–4. <a target=xrefwindow id=d23673e1875 href="http://www.ncbi.nlm.nih.gov/pubmed/23113752">PubMed Abstract </a> | <a target=xrefwindow id=d23673e1878 href="https://doi.org/10.1089/thy.2012.0103">Publisher Full Text </a> | <a target=xrefwindow id=d23673e1882 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3643255">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717964469">F1000 Recommendation</a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718026272"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23673e1895 class=n-a></a>Sosa JA, Elisei R, Jarzab B, <i> et al.</i>: Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma. <i>Thyroid.</i> 2014; <b>24</b>(2): 232–40. <a target=xrefwindow id=d23673e1906 href="http://www.ncbi.nlm.nih.gov/pubmed/23721245">PubMed Abstract </a> | <a target=xrefwindow id=d23673e1909 href="https://doi.org/10.1089/thy.2013.0078">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718026272">F1000 Recommendation</a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d23673e1922 class=n-a></a>Sosa JA, Balkissoon J, Lu SP, <i> et al.</i>: Thyroidectomy followed by fosbretabulin (CA4P) combination regimen appears to suggest improvement in patient survival in anaplastic thyroid cancer. <i>Surgery.</i> 2012; <b>152</b>(6): 1078–87. <a target=xrefwindow id=d23673e1933 href="http://www.ncbi.nlm.nih.gov/pubmed/23158178">PubMed Abstract </a> | <a target=xrefwindow id=d23673e1936 href="https://doi.org/10.1016/j.surg.2012.08.036">Publisher Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727413336"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23673e1945 class=n-a></a>Tahara M, Kiyota N, Yamazaki T, <i> et al.</i>: Lenvatinib for Anaplastic Thyroid Cancer. <i>Front Oncol.</i> 2017; <b>7</b>: 25. <a target=xrefwindow id=d23673e1956 href="http://www.ncbi.nlm.nih.gov/pubmed/28299283">PubMed Abstract </a> | <a target=xrefwindow id=d23673e1959 href="https://doi.org/10.3389/fonc.2017.00025">Publisher Full Text </a> | <a target=xrefwindow id=d23673e1963 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5331066">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727413336">F1000 Recommendation</a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727436656"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23673e1977 class=n-a></a>Chintakuntlawar AV, Rumilla KM, Smith CY, <i> et al.</i>: Expression of PD-1 and PD-L1 in Anaplastic Thyroid Cancer Patients Treated With Multimodal Therapy: Results From a Retrospective Study. <i>J Clin Endocrinol Metab.</i> 2017; <b>102</b>(6): 1943–50. <a target=xrefwindow id=d23673e1988 href="http://www.ncbi.nlm.nih.gov/pubmed/28324060">PubMed Abstract </a> | <a target=xrefwindow id=d23673e1991 href="https://doi.org/10.1210/jc.2016-3756">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727436656">F1000 Recommendation</a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727218152"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23673e2004 class=n-a></a>Ahn S, Kim TH, Kim SW, <i> et al.</i>: Comprehensive screening for PD-L1 expression in thyroid cancer. <i>Endocr Relat Cancer.</i> 2017; <b>24</b>(2): 97–106. <a target=xrefwindow id=d23673e2015 href="http://www.ncbi.nlm.nih.gov/pubmed/28093480">PubMed Abstract </a> | <a target=xrefwindow id=d23673e2018 href="https://doi.org/10.1530/ERC-16-0421">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727218152">F1000 Recommendation</a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725315207"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23673e2031 class=n-a></a>Wu H, Sun Y, Ye H, <i> et al.</i>: Anaplastic thyroid cancer: outcome and the mutation/expression profiles of potential targets. <i>Pathol Oncol Res.</i> 2015; <b>21</b>(3): 695–701. <a target=xrefwindow id=d23673e2042 href="http://www.ncbi.nlm.nih.gov/pubmed/25588542">PubMed Abstract </a> | <a target=xrefwindow id=d23673e2045 href="https://doi.org/10.1007/s12253-014-9876-5">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725315207">F1000 Recommendation</a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726265666"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23673e2058 class=n-a></a>Bastman JJ, Serracino HS, Zhu Y, <i> et al.</i>: Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer. <i>J Clin Endocrinol Metab.</i> 2016; <b>101</b>(7): 2863–73. <a target=xrefwindow id=d23673e2069 href="http://www.ncbi.nlm.nih.gov/pubmed/27045886">PubMed Abstract </a> | <a target=xrefwindow id=d23673e2072 href="https://doi.org/10.1210/jc.2015-4227">Publisher Full Text </a> | <a target=xrefwindow id=d23673e2076 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4929840">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726265666">F1000 Recommendation</a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d23673e2089 class=n-a></a>Dadu RV, Para Cuentas ER, Rodriguez Canales J, <i> et al.</i>: Anaplastic thyroid cancer is a hot immunogenic environment: immunoprofiling of a large cohort of ATC tumors. <i>Thyroid.</i> 2016; <b>26</b>(Supplement 1).</span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/720965243"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23673e2107 class=n-a></a>Ryder M, Ghossein RA, Ricarte-Filho JC, <i> et al.</i>: Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. <i>Endocr Relat Cancer.</i> 2008; <b>15</b>(4): 1069–74. <a target=xrefwindow id=d23673e2118 href="http://www.ncbi.nlm.nih.gov/pubmed/18719091">PubMed Abstract </a> | <a target=xrefwindow id=d23673e2121 href="https://doi.org/10.1677/ERC-08-0036">Publisher Full Text </a> | <a target=xrefwindow id=d23673e2125 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2648614">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/720965243">F1000 Recommendation</a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726626498"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23673e2139 class=n-a></a>Kim DI, Kim E, Kim YA, <i> et al.</i>: Macrophage Densities Correlated with CXC Chemokine Receptor 4 Expression and Related with Poor Survival in Anaplastic Thyroid Cancer. <i>Endocrinol Metab (Seoul).</i> 2016; <b>31</b>(3): 469–75. <a target=xrefwindow id=d23673e2150 href="http://www.ncbi.nlm.nih.gov/pubmed/27491720">PubMed Abstract </a> | <a target=xrefwindow id=d23673e2153 href="https://doi.org/10.3803/EnM.2016.31.3.469">Publisher Full Text </a> | <a target=xrefwindow id=d23673e2157 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5053061">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726626498">F1000 Recommendation</a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d23673e2170 class=n-a></a>Caillou B, Talbot M, Weyemi U, <i> et al.</i>: Tumor-associated macrophages (TAMs) form an interconnected cellular supportive network in anaplastic thyroid carcinoma. <i>PLoS One.</i> 2011; <b>6</b>(7): e22567. <a target=xrefwindow id=d23673e2181 href="http://www.ncbi.nlm.nih.gov/pubmed/21811634">PubMed Abstract </a> | <a target=xrefwindow id=d23673e2184 href="https://doi.org/10.1371/journal.pone.0022567">Publisher Full Text </a> | <a target=xrefwindow id=d23673e2188 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3141071">Free Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727620678"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23673e2197 class=n-a></a>Gordon SR, Maute RL, Dulken BW, <i> et al.</i>: PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. <i>Nature.</i> 2017; <b>545</b>(7655): 495–9. <a target=xrefwindow id=d23673e2208 href="http://www.ncbi.nlm.nih.gov/pubmed/28514441">PubMed Abstract </a> | <a target=xrefwindow id=d23673e2211 href="https://doi.org/10.1038/nature22396">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727620678">F1000 Recommendation</a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726191113"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d23673e2224 class=n-a></a>Brauner E, Gunda V, Vanden Borre P, <i> et al.</i>: Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer. <i>Oncotarget.</i> 2016; <b>7</b>(13): 17194–211. <a target=xrefwindow id=d23673e2235 href="http://www.ncbi.nlm.nih.gov/pubmed/26943572">PubMed Abstract </a> | <a target=xrefwindow id=d23673e2238 href="https://doi.org/10.18632/oncotarget.7839">Publisher Full Text </a> | <a target=xrefwindow id=d23673e2242 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4941380">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726191113">F1000 Recommendation</a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d23673e2255 class=n-a></a>Sandulache VC, Williams MD, Lai SY, <i> et al.</i>: Real-Time Genomic Characterization Utilizing Circulating Cell-Free DNA in Patients with Anaplastic Thyroid Carcinoma. <i>Thyroid.</i> 2017; <b>27</b>(1): 81–7. <a target=xrefwindow id=d23673e2266 href="http://www.ncbi.nlm.nih.gov/pubmed/27785980">PubMed Abstract </a> | <a target=xrefwindow id=d23673e2269 href="https://doi.org/10.1089/thy.2016.0076">Publisher Full Text </a> | <a target=xrefwindow id=d23673e2273 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5704769">Free Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d23673e2282 class=n-a></a>Cabanillas ME, Smith A, Williams MD, <i> et al.</i>: Utility of BRAF V600E Immunoperoxidase Stain in Cytology Preparations of Cell Block and Aspirate Smears in Thyroid Cancers. <i>Eur Thyroid J.</i> 2017; <b>6</b>(Suppl 1): abstr P2-02-69.</span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 18 Jan 2018</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/7-87/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/7-87/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Department of Endocrine Neoplasia &amp; Hormonal Disorders, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA<br/> <sup>2</sup> Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA<br/> <sup>3</sup> Department of Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA<br/> <sup>4</sup> Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, 515 Holcombe Blvd, Houston, TX, 77030, USA<br/> <sup>5</sup> Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA<br/> <sup>6</sup> Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA<br/> <p> <div class=margin-bottom> Maria E. Cabanillas <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation </div> <div class=margin-bottom> Mark Zafereo <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> Michelle D. Williams <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> Renata Ferrarotto <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> Ramona Dadu <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> Neil Gross <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> G. Brandon Gunn <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> Heath Skinner <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> Gilbert Cote <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> Horiana B. Grosu <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> Priyanka Iyer <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> Naifa L. Busaidy <br/> <span>Roles: </span> Writing – Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/7-87/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 18 Jan 2018, 7:87 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.13124.1">https://doi.org/10.12688/f1000research.13124.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2018 Cabanillas ME <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=14236 data-id=13124 data-downloads="" data-views="" data-scholar="10.12688/f1000research.13124.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/7-87/v1/pdf?article_uuid=45904f16-619d-400c-b8bd-c6693eee0d40" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.13124.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Cabanillas ME, Zafereo M, Williams MD <em>et al.</em> Recent advances and emerging therapies in anaplastic thyroid carcinoma [version 1; peer review: 3 approved] <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):87 (<a href="https://doi.org/10.12688/f1000research.13124.1" target=_blank>https://doi.org/10.12688/f1000research.13124.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=13124 id=mobile-track-article-signin-13124 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/13124?target=/articles/7-87/v1"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=14236 /> <input name=articleId type=hidden value=13124 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Ana O Hoff</strong>, Department of Endocrinology, Instituto do Câncer do Estado de São Paulo, Brazil </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Vera Tiedje</strong>, Department of Endocrinology and Metabolism, University Hospital Essen and University Duisburg-Essen, Germany </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Ashok R Shaha</strong>, Head and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 18 Jan 2018</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/7-87/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/7-87/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=29715-29715></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=29716-29716></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=29714-29714></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=3><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> <th class="c-report-timeline__headings-version p-article__color--dark">3</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/7-87/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>18 Jan 18</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Ana O Hoff</strong>, Department of Endocrinology, Instituto do Câncer do Estado de São Paulo, Brazil </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Vera Tiedje</strong>, Department of Endocrinology and Metabolism, University Hospital Essen and University Duisburg-Essen, Germany </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Ashok R Shaha</strong>, Head and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/7-87/v1&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/7-87/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Recent advances and emerging therapies in...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/7-87/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/7-87/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/7-87/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Cabanillas ME et al.');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/7-87/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/7-87",
            templates : {
                twitter : "Recent advances and emerging therapies in anaplastic thyroid.... Cabanillas ME et al., published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/7-87/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Recent advances and emerging therapies in anaplastic thyroid carcinoma", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Recent advances and emerging therapies in anaplastic thyroid carcinoma", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/13124/14236")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "14236");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "29714": 0,
                           "29715": 0,
                           "29716": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "9652c83f-184b-4f30-a390-1771e3402a47";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-87.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-87.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-87.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/7-87.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/7-87.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>